158654-96-7

Usage

Uses

Used in Pharmaceutical Research:
4-(1H-Imidazol-2-yl)-1-piperidinecarboxylic acid 1,1-dimethylethyl ester is used as a research compound for its potential role in the development of new drugs. Its unique structure and properties contribute to the exploration of its therapeutic potential in various medical conditions.
Used in Medicinal Chemistry:
In the field of medicinal chemistry, 4-(1H-Imidazol-2-yl)-1-piperidinecarboxylic acid 1,1-dimethylethyl ester serves as a building block for the synthesis of complex molecules with potential pharmaceutical applications. Its incorporation into drug candidates can enhance their efficacy and selectivity.
Used in Drug Design and Synthesis:
The chemical structure of 4-(1H-Imidazol-2-yl)-1-piperidinecarboxylic acid 1,1-dimethylethyl ester makes it a valuable compound for drug design and synthesis. It can be modified and combined with other chemical entities to create novel drug candidates with improved pharmacological profiles.
Used in Drug Discovery:
As a target for drug discovery, 4-(1H-Imidazol-2-yl)-1-piperidinecarboxylic acid 1,1-dimethylethyl ester is investigated for its potential biological activities. Its exploration can lead to the identification of new therapeutic agents with specific mechanisms of action.
Used in Chemical Synthesis Industry:
In the chemical synthesis industry, 4-(1H-Imidazol-2-yl)-1-piperidinecarboxylic acid 1,1-dimethylethyl ester is utilized as a key intermediate in the synthesis of various pharmaceuticals and other related compounds, contributing to the development of innovative products.

InChI:InChI=1/C13H21N3O2/c1-13(2,3)18-12(17)16-8-4-10(5-9-16)11-14-6-7-15-11/h6-7,10H,4-5,8-9H2,1-3H3,(H,14,15)

Upstream product

• 375853-82-0 tert-Butyl 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,6-dihydro-1(2H)-pyridinecarboxylate 
• 131543-46-9 Glyoxal 
• 137076-22-3 tert butyl 4-formylpiperidine-1-carboxylate 
• 158654-94-5 tert-butyl 4-(1H-imidazol-2-yl)-5,6-dihydropyridine-1(2H)-carboxylate 

Downstream Products

• 90747-46-9 4-(1H-lmidazol-2-yl)piperidine dihydrochloride 
• 1428252-97-4 4-[1-(2-azetidin-1-ylethyl)-4-(4-fluoro-3-methylphenyl)-1H-imidazol-2-yl]piperidine-1-carboxylic acid tert-butyl ester 
• 1428253-42-2 4-(1-(2-(azetidin-1-yl)ethyl)-4-(4-fluoro-3-methylphenyl)-1H-imidazol-2-yl)piperidine 
• 1428253-14-8 2-[4-(4-fluoro-3-methylphenyl)-2-piperidin-4-yl-imidazol-1-yl]ethyl-dimethylamine 
• 1428252-95-2 4-[4-(4-fluoro-3-methylphenyl)-1-(2-hydroxyethyl)-1H-imidazol-2-yl]piperidine-1-carboxylic acid tert-butyl ester 
• 1428250-29-6 6-(4-(1-(2-(cyclopropylamino)ethyl)-4-(4-fluoro-3-methylphenyl)-1H-imidazol-2-yl)piperidin-1-yl)-5-(1H-pyrazol-4-yl)pyrimidin-4-amine 
• 1428253-12-6 tert-butyl 4-(4-amino-6-(4-(4-(4-fluoro-3-methylphenyl)-1-(2-((methylsulfonyl)oxy)ethyl)-1H-imidazol-2-yl)piperidin-1-yl)pyrimidin-5-yl)-1H-pyrazole-1-carboxylate 
• 1446104-05-7 2-(2-(1-(6-amino-5-bromopyrimidin-4-yl)piperidin-4-yl)-4-(4-fluoro-3-methylphenyl)-1H-imidazol-1-yl)ethanol 
• 1428250-28-5 2-(2-(1-(6-amino-5-(1H-pyrazol-4-yl)pyrimidin-4-yl)piperidin-4-yl)-4-(4-fluoro-3-methylphenyl)-1H-imidazol-1-yl)ethanol 

Relevant academic research and scientific papers

TETRAHYDROQUINOLINE COMPOSITIONS AS BET BROMODOMAIN INHIBITORS

The present invention relates to inhibitors of bromo and extra terminal (BET) bromodomains that are useful for the treatment of cancer, inflammatory diseases, diabetes, and obesity, having Formula (I): wherein W, X, Y, Z, R1, R2, R5, and R8 are as described herein.

N1-(3,3,3-TRIFLUORO-2-HYDROXO-2-METHYLPROPIONYL)-PIPERIDINE DERIVATIVES AS INHIBITORS OF PYRUVATE DEHYDROGENASE KINASE

Compounds of the formula (I) in which R, R1 and R3 have the meanings indicated in Claim 1, are inhibitors of pyruvate dehydrogenase kinase (PDHK), and can be employed, inter alia, for the treatment of diseases such as cancer.

NOVEL IMIDAZOLE AMINES AS MODULATORS OF KINASE ACTIVITY

The invention provides novel imidazole amine compounds according to Formula (I) and Formula (II) their manufacture and use for the treatment of hyperproliferative diseases, such as cancer.

AKT INHIBITORS

The present invention provides AKT inhibitors of the formula: Formula I The present invention also provides pharmaceutical compositions comprising compounds of Formula I, uses of compounds of Formula I and method of using compounds of Formula I.

SEROTONIN 5-HT2B RECEPTOR INHIBITORS

Disclosed are Serotonin 5-HT2B receptor inhibitors of the formula I. Also disclosed are methods of making and methods of using these compounds

A new class of 5-HT2B antagonists possesses favorable potency, selectivity, and rat pharmacokinetic properties

We have been exploring the potential of 5-HT2B antagonists as a therapy for chronic heart failure. To assess the potential of this therapeutic approach, we sought compounds possessing the following attributes: (a) potent and selective antagonis

HETEROARYLPIPERIDINE MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY

The present invention is directed to compounds of the formula (I): (wherein R>12345610 and n are defined herein) which are useful as modulators of chemokine receptor activity. In particular, these compounds are useful as modulators of the chemokine receptor CCR-2.